Australian superannuation fund Hostplus has committed $50 million to a China-focused VC fund launched by Australian seed investor Artesian. The fund is targeting up to $200 million.
Yatra Online, an Indian travel services provider listed on NASDAQ, has raised INR1 billion ($15.4 million) in debt funding from InnoVen Capital.
East Ventures has launched a $30 million Southeast Asia fund that will make seed to Series A investments in technology start-ups, with an emphasis on Indonesia.
Réal Desrochers, formerly head of private equity at the California Public Employees’ Retirement System (CalPERS), has joined Beijing-based CITIC Private Equity (CITIC PE) as a managing director.
China-based Drum Tower Ventures has launched its first fund, with a view to raising $50 million for early-stage investments globally.
Madison India Capital has reached a final close of $230 million on its latest fund, Madison India Opportunities IV.
Pacific Equity Partners (PEP), currently Australia’s largest domestic buyout player, plans to raise an infrastructure fund with a view to applying operational knowhow from private equity to investments in a different asset class.
Japan’s Mizuho Bank has launched a private equity fund focused on middle-market companies in the ASEAN region with a target corpus of $250 million.
Shanghai Fosun Pharmaceutical has altered the terms of its acquisition of a majority stake in India-based Gland Pharma – a deal that will facilitate an exit for KKR – as part of a long-running battle to win regulatory approval.
Taiwan-based hardware giant Asus has launched a $50 million VC fund aimed at helping US start-ups expand in Asia.
US President Donald Trump has vetoed the sale of US-based chip maker Lattice Semiconductor to Canyon Bridge Capital Partners, a private equity firm backed by Chinese LPs, citing national security concerns.
Kedaara Capital has closed its second India-focused fund at the hard cap of $750 million after approximately six months in the market.
Insignia Ventures Partners, a Singapore-based VC firm founded by former Sequoia Capital India venture partner Yinglan Tan, has raised $25 million for its debut fund.
Asia Alternatives has reached a final close of $1.8 billion across its fifth private equity fund-of-funds and a number of related vehicles.
The Asian Development Bank (ADB) has invested $60 million in OrbiMed Asia Partners III, the third Asian private equity fund of healthcare-focused GP OrbiMed.
Singapore investor Golden Equator Capital and Korean research organization C&R Healthcare Global have jointly launched an incubation program that will help Korean healthcare start-ups execute Asian expansions via Singapore.
Australian institutional investors are responding to rising valuations in the core infrastructure space by moving up the risk curve into more opportunistic assets – and domestic pricing pressure is also expected to lead to higher emerging markets allocations.
Government-owned Malaysia Debt Ventures (MDV) has launched its third fund with a view to investing up to MYR4 billion ($954 million) in technology companies across the next 20 years.
The International Finance Corporation (IFC) has proposed an investment of up to $25 million in the debut fund of GenBridge Capital, a private equity firm set up by former executives from JD.com and TPG Capital that focuses on China’s consumer sector.
Start-up fundraisings via the sale of cryptographic tokens, also known as initial coin offerings (ICO), are set to experience elevated legal enforcement risk in Asia following regulatory pressure in China and Hong Kong.
Bain Capital Credit has reached a first close of $557 million on its Asia-focused special situations fund.
China-based start-up incubator and early-stage investor Withinlink is targeting $30 million for its second venture capital fund to help US companies enter the Chinese market.
Healthcare-focused investment firm OrbiMed has closed its third Asian private equity fund with $551 million in commitments.
Eight Roads Ventures, the proprietary investment arm of Fidelity International, has launched its debut China healthcare fund worth $250 million. All the capital comes from the firm's parent.